- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05656560
La reducción de la polifarmacia geriátrica de alto riesgo a través de EHR Nudges R01 Trial (HRPP)
Reducción de la polifarmacia de alto riesgo utilizando la economía del comportamiento a través de registros de salud electrónicos
High-risk polypharmacy is common among older adults in the United States, is particularly dangerous for individuals with dementia or cognitive impairment, and is associated with harms such as adverse drug reactions, falls, and higher costs of care. This project aims to test in a pragmatic clinic-randomized controlled trial two electronic health record-based behavioral economic nudges to help clinicians reduce high-risk polypharmacy among their older adult patients and in the subgroup with dementia or cognitive impairment.
The main questions this trial aims to answer are:
Aim 1: To evaluate the effects of an EHR-based commitment nudge, a justification nudge, and the combination of both nudges on a composite measure of high-risk polypharmacy via a pragmatic randomized controlled trial. The investigators will use cluster randomization in which primary care clinics are randomized to receive 0, 1, or 2 nudges using a factorial design. The nudges will run for 18 months, followed by 12 months of observation to assess persistence of effects.
Aim 2: To qualitatively and quantitatively assess clinician experiences with the EHR-based nudges, including their acceptability and effects on workflow. At the conclusion of the intervention period, the investigators will perform semi-structured interviews and field a clinician survey.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern Medicine
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- UPMC
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Northwestern Medicine or UPMC primary care clinic: Internal Medicine, Family Medicine, or General Practice or Geriatrics
Exclusion Criteria:
- None
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación factorial
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Clinician education only
Online clinician education |
Brief, online education module for primary care clinicians |
|
Experimental: Commitment nudge
The commitment nudge will be an EHR alert that is triggered when a clinician renews or orders a qualifying medication in any Epic encounter (including non-face-to-face encounters) for a patient aged 65 or greater who meets criteria for high-risk polypharmacy. When triggered, the commitment nudge will offer the clinician a choice option that sets a reminder to discuss polypharmacy at the patient's next visit date. |
Brief, online education module for primary care clinicians EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
Otros nombres:
|
|
Experimental: Justification nudge
The justification nudge will be an EHR alert triggered for patients with high-risk polypharmacy when a clinician begins to renew or newly prescribe a medication that causes a high-risk criterion to be fulfilled (i.e., a medication meeting causing 1 of the 7 high-risk polypharmacy criteria/primary study measures to be met). This alert will inform the clinician of the high-risk nature of the prescription and request a free-text justification for starting or renewing the medication. This written justification will appear in the EHR in a section of that encounter that other EHR users can see. |
Brief, online education module for primary care clinicians EHR clinical decision support alerts-clinician rational for high risk polypharmacy
Otros nombres:
|
|
Experimental: Commitment nudge + Justification nudge
This study arm will receive both the commitment nudge and the justification nudge. |
Brief, online education module for primary care clinicians EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
Otros nombres:
EHR clinical decision support alerts-clinician rational for high risk polypharmacy
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The percentage of HRPP with any (1 or more) of the 7 measures of high risk polypharmacy. (Composite measure)
Periodo de tiempo: 18 months
|
The composite of the 7 high-risk polypharmacy measures (Secondary outcomes #6-12) |
18 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The rate of Emergency Department visits per patient -all cause
Periodo de tiempo: 18 months
|
Denominator: All older adults with HRPP. Numerator: Patients with an emergency department encounter during the look back period. |
18 months
|
|
The rate of Emergency Department visits per patient-Adverse drug event (ADE)-specific
Periodo de tiempo: 18 months
|
Denominator: All older adults with HRPP. Numerator: Patients with an emergency department encounter for ADE during the look back period. |
18 months
|
|
The rate of hospital admissions per patient-all cause
Periodo de tiempo: 18 months
|
Denominator: All older adults with HRPP. Numerator: Patients with an inpatient admission for any reason during the look back period. |
18 months
|
|
The rate of hospital admissions per patient-ADE-specific
Periodo de tiempo: 18 months
|
Denominator: All older adults with HRPP. Numerator: Patients with an inpatient admission for ADE during the look back period. |
18 months
|
|
The percentage of HRPP patients with a fall condition-drug interaction
Periodo de tiempo: 18 months
|
Denominator: All older adult patients with HRPP with a fall marker. Numerator: Patients with an active eligible fall risk medication on medication list. |
18 months
|
|
The percentage of HRPP patients with a fall drug-drug interaction
Periodo de tiempo: 18 months
|
Denominator: All older adult patients with HRPP. Numerator: Patients with greater than or equal to 3 active eligible fall risk medications. |
18 months
|
|
The percentage of HRPP patients with Heart failure-NSAID interaction
Periodo de tiempo: 18 months
|
Denominator: All older adult patients with HRPP with a CHF marker. Numerator: Patients with an active eligible NSAID medication. |
18 months
|
|
The percentage of HRPP patients with Heart Failure-thiazolidinedione interaction
Periodo de tiempo: 18 months
|
Denominator: All older adults with HRPP with a CHF marker. Numerator: Patients with an active eligible thiazolidinedione medication. |
18 months
|
|
The percentage of HRPP patients with Heart failure with reduced ejection fraction- non-dihydropyridine calcium channel blocker interaction
Periodo de tiempo: 18 months
|
Denominator: All older adults with HRPP with CHFlowEF marker. Numerator: Patients with an active eligible calcium channel blocker medication. |
18 months
|
|
The percentage of HRPP patients with CKD-glyburide/glimepiride interaction
Periodo de tiempo: 18 months
|
Denominator: All older adults with HRPP with most-recent eGFR <60. Numerator: Patients with an active eligible glyburide-containing medication. |
18 months
|
|
The percentage of HRPP patients with CKD-NSAID interaction
Periodo de tiempo: 18 months
|
Denominator: All older adults with HRPP with most-recent eGFR < 30. Numerator: Patients with an active eligible NSAID medication. |
18 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The percentage of HRPP patients with a hospitalization or emergency department (ED) visit for seizure.
Periodo de tiempo: 18 months
|
Safety measure for discontinuing or reducing benzodiazepines and anticonvulsants |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for pain.
Periodo de tiempo: 18 months
|
Safety measure for discontinuing or reducing tricyclic antidepressants, gabapentinoids, serotonin and norepinephrine reuptake inhibitors, opioids, and NSAIDs |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for depression or suicidality
Periodo de tiempo: 18 months
|
Safety measure for discontinuing or reducing tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for anxiety.
Periodo de tiempo: 18 months
|
Safety measure for discontinuing or reducing benzodiazepines, serotonin and norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for sedative withdrawal.
Periodo de tiempo: 18 months
|
Safety measure for discontinuing or reducing benzodiazepines and Z-drugs (GABA receptor modulators) |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for opioid withdrawal.
Periodo de tiempo: 18 months
|
Safety measure for discontinuing or reducing opioids |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for behavioral disturbance in dementia or psychosis.
Periodo de tiempo: 18 months
|
Safety measure for discontinuing or reducing antipsychotics |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for hyperglycemia.
Periodo de tiempo: 18 months
|
Safety measure for discontinuing or reducing glyburide, glimepiride, and thiazolidinediones |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for tachycardia (other than ventricular) or hypertensive emergency.
Periodo de tiempo: 18 months
|
Safety measure for discontinuing or reducing non-dihydropyridine calcium channel blockers |
18 months
|
Colaboradores e Investigadores
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- STU00213231
- R01AG070054 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .